ducovest

PPH:NSD-VanEck Vectors Pharmaceutical ETF (USD)

ETF | Health | NASDAQ Global Market

Last Closing

USD 90.89

Change

+0.97 (+1.08)%

Market Cap

USD 0.25B

Volume

0.45M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

The investment seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Market Vectors? US Listed Pharmaceutical 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Pharmaceutical Index is comprised of common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical sector. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

Company Website : www.marketvectorsetfs.com

Currency: USD

Country : USA

Inception Date: 20/12/2011

Primary Benchmark: MVIS US Listed Pharmaceutical 25 NR USD

Primary Index: MSCI ACWI NR USD

Gross Expense Ratio: 0.41%

Management Expense Ratio: 0.36 %

Unadjusted Closing Price

Adjusted Closing Price

Assets

N/A

Top Holdings

N/A

Symbol Company Name Allocation
LLY Eli Lilly and Company 11.73 %
NVO Novo Nordisk A/S 9.83 %
JNJ Johnson & Johnson 6.56 %
MRK Merck & Company Inc 6.23 %
ABBV AbbVie Inc 5.88 %
AZN AstraZeneca PLC ADR 5.59 %
NVS Novartis AG ADR 4.93 %
MCK McKesson Corporation 4.70 %
BW Babcock & Wilcox Enterprises Inc 4.69 %
Top Sectors

N/A

Top Regions

N/A

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-03-27 )

Largest Industry Peers for Health

Symbol Name Mer Price(Change) Market Cap
IBB iShares Biotechnology ETF 0.47 %

N/A

 USD 6.95B
BBH VanEck Biotech ETF 0.35 %

N/A

 USD 0.41B
PSCH Invesco S&P SmallCap Health Ca.. 0.29 %

N/A

 USD 0.20B
PTH Invesco DWA Healthcare Momentu.. 0.60 %

N/A

 USD 0.13B
GNOM Global X Genomics & Biotechnol.. 0.00 %

N/A

 USD 0.09B
BTEC Principal Healthcare Innovator.. 0.42 %

N/A

 USD 0.04B
FTXH First Trust Nasdaq Pharmaceuti.. 0.60 %

N/A

 USD 0.02B
CNCR Loncar Cancer Immunotherapy ET.. 0.79 %

N/A

 USD 0.02B

ETFs Containing PPH

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 11.70% 78% C+ 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 11.70% 78% C+ 74% C
Trailing 12 Months  
Capital Gain 18.45% 89% A- 72% C
Dividend Return 2.22% 100% F 34% F
Total Return 20.67% 89% A- 72% C
Trailing 5 Years  
Capital Gain 49.69% 88% B+ 73% C
Dividend Return 9.51% 86% B+ 39% F
Total Return 59.20% 88% B+ 73% C
Average Annual (5 Year Horizon)  
Capital Gain 8.09% 89% A- 68% D+
Dividend Return 9.77% 89% A- 68% D+
Total Return 1.67% 88% B+ 42% F
Risk Return Profile  
Volatility (Standard Deviation) 9.17% 89% A- 87% B+
Risk Adjusted Return 106.55% 100% F 99% N/A
Market Capitalization 0.25B 89% A- 63% D

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.